The first-ever systematic study of the genomes of patients with ALK-negative anaplastic large cell lymphoma (ALCL), a particularly aggressive form of non-Hodgkin's lymphoma, shows that many cases of ...
A new study identifies the RAS-MAPK pathway to be an Achilles' heel of EML4-ALK fusion-positive lung cancer and suggests that up-front combination therapy directed against both pathways can achieve ...
Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data The robust and sustained clinical responses to ...
A clinical pathway blends expertise from many providers. The primary goal of a clinical pathway is to produce maximum value at each practice site. Dr Konduri’s institution strongly emphasizes the ...
Crizotinib induced robust and sustained clinical responses in children with relapsed anaplastic large cell lymphoma and metastatic or unresectable inflammatory myofibroblastic tumors, according to a ...
AUSTIN, Texas , Oct. 24, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...
Life-or-death verdicts in cancer often result from the ways microscopic kinks and folds in proteins fit together within a tumor cell. While in college, Trever Bivona, MD, PhD, was fascinated by the ...
The first-ever systematic study of the genomes of patients with ALK-negative anaplastic large cell lymphoma, a particularly aggressive form of non-Hodgkin's lymphoma, has been concluded. The findings ...
Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumor growth, is active in patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback